Regulatory31 October 2026· 8 min read
Weltruza Olanzapine Injection Gets FDA Approval in Schizophrenia
In the SOLARIS trial, Weltruza lowered schizophrenia symptom scores by 9.75 to 11.27 points more than placebo at 8 weeks, with more weight gain and no peer-reviewed report yet. It is not approved in the UK or EU.
By Pharma Journal Editorial Desk, Editorial Desk
Regulatory30 October 2026· 9 min read
Merz Aesthetics Products and How Each Is Regulated in the UK
Only Bocouture holds an MHRA licence among Merz Aesthetics products; Belotero, Radiesse and Ultherapy are regulated as devices. Here is what that means.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Regulatory22 October 2026· 10 min read
What Touchlight's Cell-Free DNA Manufacturing Licence Covers
Touchlight's cell-free DNA manufacturing won a CPHI award, but what do the MHRA certificate and FDA Drug Master File actually say? We read both documents.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Regulatory20 October 2026· 9 min read
FDA Approves Atezolizumab for Stage III dMMR Colon Cancer
The FDA approved atezolizumab for stage III dMMR colon cancer on 8 October 2026. Here is what the ATOMIC trial numbers actually show — and what remains unknown.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Research16 October 2026· 6 min read
AstraZeneca and insitro Sign AI Deal for MASH and Heart Disease
AstraZeneca and insitro have signed a $40m AI collaboration targeting MASH and cardiomyopathies, with up to $1.46bn in milestones. Here is what the terms mean.
By Priya Raghavan, Biotech & Markets Analyst
News13 October 2026· 8 min read
PCSK9 Inhibitors and LDL Reduction Beyond the Statin Ceiling
PCSK9 inhibitors reduce LDL-C by up to 60% on top of statins. Explore the mechanism, FOURIER and ODYSSEY OUTCOMES trial data, and current UK NICE prescribing criteria.
By Tom Okafor, Clinical Trials Correspondent
Clinical Trials5 October 2026· 7 min read
What the New UK Clinical Trials Regulations Mean for Sponsors
The UK's new clinical trials regulations enter force 28 April 2026. Here is what the notification scheme, combined review, and results disclosure obligations mean for sponsors and CROs.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Treatments28 September 2026· 6 min read
Biocon Pertuzumab Biosimilar Pebrilzo Wins CHMP Opinion
Biocon's pertuzumab biosimilar Pebrilzo has received a positive CHMP opinion — the first monoclonal antibody biosimilar under the EMA's tailored clinical development approach for HER2-positive breast cancer.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Treatments24 September 2026· 3 min read
FDA Approves Imlunestrant Combination for ESR1 Breast Cancer
The FDA has fully approved imlunestrant plus abemaciclib for ESR1-mutated ER-positive breast cancer, with EMBER-3 showing 11.1 vs 5.5 months PFS. Read on.
By Tom Okafor, Clinical Trials Correspondent
Regulatory21 September 2026· 8 min read
FDA Clears Finerenone for Type 1 Diabetes Kidney Disease
A 242-patient trial with a urinary biomarker endpoint has carried finerenone into a new US indication. The number that matters is not the 25% in the headlines, and no UK or EU decision for type 1 diabetes has been reported.
By Tom Okafor, Clinical Trials Correspondent
Regulatory21 September 2026· 8 min read
OS Therapies Project Orbis MHRA Osteosarcoma Signal
MHRA asked OS Therapies to bring OST-HER2 into Project Orbis and accepted literature-derived historical controls in resected metastatic osteosarcoma. The procedural precedent matters more than the candidate, and every load-bearing fact is the sponsor's.
By Dr. Eleanor Vance, Regulatory Affairs Editor